Cipla Limited up by 5.46 percent: Market Update By Espresso

EspressoLogy

Espresso Shot of the Day - Cipla Ltd up by 5.46 percent

September 20, 2022
Espresso Shot of the Day - Cipla Ltd up by 5.46 percent

CIPLA LTD 1091.40 (+5.46%) BSE –INE066O01014| 20th September 2022

https://www.myespresso.com/images/Binge-graph-image_Cipla-Ltd-202209201859253913737.jpg

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally. Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.


Recent Drivers

  • On September 13,2022 Cipla has allotted 5,683 equity shares of Rs 2 each, pursuant to exercise of employee stock options /stock appreciation rights under the Employee Stock Option Scheme of the Company.
  • Drug firm Cipla on September 7,2022 said it has received approval from the US health regulator for Lenalidomide capsule, a drug used to treat various types of cancer. The company has received the final approval from the US Food and Drug Administration (USFDA) for the product in strengths of 5 mg, 10 mg, 15 mg and 25 mg, Cipla said in a regulatory filing.
  • Cipla Ltd announced that its board has approved the appointment of Ashish Adukia as the global chief financial officer (CFO) and key managerial personnel of the company with effect from 16 August 2022.
  • On July 29,2022, the Company reported Quarterly Net Profit of Rs. 706.14 crore in June 2022.
  • On July 29,2022, the Company reported Quarterly Net Sales at Rs 5,375.19 crore in June 2022.
  • Company have recommended final dividend of Rs 5/- per equity share for FY 2021-22 on July 27,2022, subject to the approval of the shareholders at the ensuing 86th Annual General Meeting.
  • Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on June 27,2022. This investment will further strengthen our partnership with GoApptiv enabling wider patient reach with affordable and quality drugs and end-to-end brand marketing and channel engagement across tier 2-6 towns in India.
(Sources: BSE, Money control, BusinessStandard)
                                                            

Technical Force*

  • S&P BSE 100 month till date gain by 0.59%.
  • 3 months avg. NSE volume: 1,459,110.
  • Quantity traded: 57,367| Deliverable quantity: 20,698 (36.08%).
  • Stock price jumped by more than 20 % from a one-year low level: 850.00 (December 17, 2021)
  • Daily RSI (14) is near oversold territory today.
  • 52-week-high: 1096.90| 52-week-low: 850.00.


Key Pivot (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

1320.20

1162.60

1053.45

895.85

786.70

629.10

519.95

66.37

Fibonacci Pivot

1162.60

1060.70

997.75

957.20

895.85

834.50

793.95

731.00

629.10


Today’s Close

1091.40

SMA

BSE

10 DAY

1055.21

20 DAY

1041.81

50 DAY

1011.66

200 DAY

966.86


Some Key Ratios (Source: BSE)

Market Cap:  88,075.53 Crores

PE:  30.10

OPM%: 30.88

ROE%:  12.99

Promoters holding%: 33.61

Prev. Close:  1034.85


https://www.myespresso.com/images/espresso_shot_blog_credit_image%20WD-202206271809546799546.jpg

Chart and Technical Force data from the Binge desktop app

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan Comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comrade Private Limited is under no obligation to update the information in this document from time-to-time


Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.